Effect of High‐Dose Vitamin C on the Steady‐State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers
Authors:
- 1 February 2005
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (2) , 165-170
Abstract
Study Objective. To determine whether daily high‐dose vitamin C alters the steady‐state pharmacokinetics of indinavir, a protease inhibitor indicated for treatment of the human immunodeficiency virus type 1. Design. Prospective, open‐label, longitudinal, two‐period time series. Setting. University medical center. Subjects. Seven healthy volunteers. Intervention. Indinavir 800 mg every 8 hours was given to subjects for four doses on days 1 and 2. Plasma samples were then collected for indinavir pharmacokinetic determination. After a 7‐day washout period, subjects were given vitamin C 1000 mg/day for 7 days. Beginning on day 6 of vitamin C administration, indinavir 800 mg every 8 hours was restarted for four doses. Plasma was then collected from subjects to determine indinavir pharmacokinetics. All subjects were given a vitamin C content–controlled diet for 1 week before the study began and throughout the study period. Measurements and Main Results. Steady‐state plasma samples were collected before dosing (0 hr) and 0.5, 1, 2, 3, 4, and 5 hours after dosing to determine indinavir pharmacokinetics. Parameters of interest were maximum plasma concentration (C max ), time to C max , area under the plasma concentration–time curve from 0–5 hours after the dose (AUC 0–5 ), an extrapolated 8‐hour AUC (AUC 0–8 ), trough (minimum) plasma concentration (C min ), and oral clearance. Mean steady‐state indinavir C max was significantly reduced (20%) after 7 days of vitamin C administration (10.3 ± 1.5 vs 8.2 ± 2.9 μg/ml, p=0.04). The corresponding mean AUC 0–8 was also significantly decreased (14%; 26.4 ± 7.2 vs 22.7 ± 8.1 μg·hr/ml, p=0.05). Although not statistically significant, the mean indinavir C min was 32% lower in the presence of vitamin C (0.27 ± 0.17 C vs 0.18 ± 0.08 μg/ml, p=0.09). Indinavir oral clearance and half‐life were not significantly different. Conclusion. Concomitant administration of high doses of vitamin C can reduce steady‐state indinavir plasma concentrations. Subtherapeutic concentrations of antiretroviral agents have been associated with viral resistance and regimen failure, but the clinical significance of our findings remains to be established.Keywords
This publication has 25 references indexed in Scilit:
- The Mucosa of the Small IntestineClinical Pharmacokinetics, 2002
- Alternative medicine use in HIV-positive men and women: Demographics, utilization patterns and health statusAIDS Care, 2001
- Interactions among Drugs for HIV and Opportunistic InfectionsNew England Journal of Medicine, 2001
- Indinavir concentrations and St John's wortThe Lancet, 2000
- Role of pharmacokinetics in the discovery and development of indinavirAdvanced Drug Delivery Reviews, 1999
- Regulation of CYP1A and CYP3A mRNAs by Ascorbic Acid in Guinea PigsArchives of Biochemistry and Biophysics, 1997
- Ascorbic Acid Protects Guinea Pigs from Acute Aflatoxin ToxicityToxicology and Applied Pharmacology, 1997
- Stimulation of drug metabolism by ascorbic acid in weanling guinea-pigsBiochemical Pharmacology, 1974
- The Role of Ascorbic Acid in Drug MetabolismDrug Metabolism Reviews, 1974
- Ascorbic acid and drug metabolismBiochemical Pharmacology, 1972